Charles Rowland

Charles is a strategic advisor and board member for multiple biotech companies including Orchard Therapeutics, where he brings more than 30 years of biopharmaceutical industry experience. Charles was most recently the president and chief executive officer of Aurinia Pharmaceuticals, a clinical-stage pharmaceutical company focused on the global lupus nephritis market. Prior to Aurinia, he served as vice president and chief financial officer of ViroPharma, during which time the company grew into a global biopharmaceutical rare diseases business before being acquired by Shire plc. Charles has held finance, operational and executive positions at Endo, Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia, Novartis, and Bristol-Myers Squibb, and serves as a member of the board of directors for Blueprint Medicines, Nabriva Therapeutics, Viking Therapeutics, and Generation Bio.

Charles holds an MBA from Rutgers University and a B.S. from Saint Joseph’s University.